Getz Healthcare Partners with Subtle Medical to Improve Medical Imaging with AI-powered Technology

Getz Healthcare Pty Ltd announced today that they have partnered with Subtle Medical, a U.S-based healthcare technology company, to distribute the company’s artificial intelligence (AI)-based software solutions for faster and safer medical imaging. Subtle’s solutions could provide significant efficiency gains for hospitals and private radiology clinics within Australia and New Zealand, resulting in more timely patient access to critical PET and MRI imaging services.

Subtle Medical’s software solution, SubtlePET™, uses proprietary deep learning algorithms to denoise low count PET images from up to 75% lower radiotracer dose and faster scan times. SubtleMR™ uses increased sharpness and denoising to improve the image quality on up to 60% faster MRI exams. The solutions result in a broad range of benefits including faster scan times, lower radiation dose, improved image quality, higher scanner efficiency, and positive impacts on workflow and patient experience. Subtle’s solutions are compatible across all PET and MRI scanner brands, makes, and models, and seamlessly integrate into existing workflows.

“We are thrilled to be expanding patient access to our AI solutions. Our goal is to not only make medical imaging safer and more focused on the patient, but also help imaging institutions and radiologists achieve higher-quality imaging while running a more efficient operation. We are looking forward to a productive partnership with Getz,” said Josh Gurewitz, Chief Commercial Officer at Subtle Medical.

James Simkins, CEO, Getz Healthcare, added, “We are really excited to be partnering with Subtle Medical. We believe Subtle Medical’s software solution will bring tangible benefits to our customers and ultimately patients.” “The possibility for Subtle Medical’s software solutions to improve efficiency and image quality while extending the life of existing imaging systems is a real game changer for radiologists and patients in need of access to imaging. We are delighted to introduce this technology to Australia and New Zealand,” said Kimberly Hill, Managing Director of Getz Healthcare Australia & New Zealand.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”